REFILE-UPDATE 1-Roche says out-licenses orlistat rights to Glaxo
(Refiles to adds UPDATE 1 tag to headline)
(Adds more detail)
ZURICH, Feb 20 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) said on Tuesday it had agreed to out-license the non-prescription rights to anti-obesity treatment orlistat outside the United States to GlaxoSmithKline Plc (GSK.L).
Roche retains all rights to the prescription version of orlistat and continued to market it under the brand name Xenical 120mg, it said in a statement.
Roche will receive an upfront payment from Glaxo. Terms were not disclosed.
The two companies have also agreed to settle all arbitration procedures related to licensing and co-marketing blood pressure treatment carvedilol, Roche said.
The Swiss company will make an undisclosed payment to Glaxo for which sufficient financial provisions have already been made.
((Reporting by Sam Cage,
Editing by Quentin Bryar
Email: zurich.newsroom@reuters.com
Reuters Messaging: sam.cage.reuters.com@reuters.net
Telephone: +41 (0) 44 631 7457)) Keywords: ROCHE GLAXO
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL2042854
